What is it about?

Disease progression and treatment response in a murine model of chronic obstructive pulmonary disease (COPD) were investigated using a preclinical hyperpolarized 129Xe (HPXe) MRI strategy. In the present study, the potential efficacy of Ethyl Pyruvate for COPD therapy is demonstrated as assessed by a non-invasive, translatable 129Xe MRI procedure.

Featured Image

Why is it important?

The feasibility of HPXe MRI for longitudinal assessment of disease progression and pharmacological therapy has been demonstrated in a mouse model of COPD. To the best of our knowledge, this is the first evidence of the therapeutic action of EP in a murine COPD model, as measured by HPXe MRI.

Perspectives

The strategy using longitudinal HPXe MRI assessment may help to explore novel drugs and elucidate the exact mechanisms of their therapeutic action in the future.

Dr Atsuomi Kimura
Osaka University

Read the Original

This page is a summary of: Treatment response of ethyl pyruvate in a mouse model of chronic obstructive pulmonary disease studied by hyperpolarized129Xe MRI, Magnetic Resonance in Medicine, September 2016, Wiley,
DOI: 10.1002/mrm.26458.
You can read the full text:

Read

Contributors

The following have contributed to this page